- Home
- VCV vs CELC Comparison
VCV vs CELC Comparison
Compare VCV & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VCV | CELC |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.8M | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VCV | CELC |
|---|---|---|
| Price | $10.85 | $105.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $100.13 |
| AVG Volume (30 Days) | 107.9K | ★ 945.1K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $75.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.05 | $7.58 |
| 52 Week High | $10.40 | $112.64 |
Technical Indicators
Market Signals| Indicator | VCV | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 70.65 |
| Support Level | $10.49 | $100.00 |
| Resistance Level | $11.12 | $108.91 |
| Average True Range (ATR) | 0.17 | 5.14 |
| MACD | 0.01 | -0.88 |
| Stochastic Oscillator | 59.20 | 54.47 |
Price Performance
Historical ComparisonAbout VCV Invesco California Value Municipal Income Trust
Invesco California Value Municipal Income Trust is engaged in the field of financial services. Its objective is to seek to provide common shareholders with a high level of current income exempt from federal and California income taxes, consistent with preservation of capital.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.